SCHEMBL4254034

SCHEMBL4254034

c1ccc2[nH]c(-c3ccc4nc[nH]c4c3)nc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.62
RAB9A P51151 12/20 0.62
SMN1; SMN2 Q16637 10/20 0.62
POLB P06746 3/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
GAA P10253 1/20 0.56
QPCT Q16769 2/20 0.55
QPCTL Q9NXS2 2/20 0.55
KDM4E B2RXH2 11/20 0.55
ALDH1A1 P00352 11/20 0.55
HPGD P15428 7/20 0.55
TP53 P04637 4/20 0.55
MAPT P10636 5/20 0.54
HSD17B10 Q99714 4/20 0.54
GFER P55789 1/20 0.54
PKM P14618 4/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31050185 1.00 NPC1 (0.62) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL6004927 0.94 NPC1 (0.57) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL25833149 0.90 NPC1 (0.52) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL14669311 0.88 QPCT (0.57) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL30822560 0.88 NPC1 (0.56) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL2569383 0.88 NPC1 (0.56) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL20847438 0.87 QPCT (0.58) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL2686936 0.87 NPC1 (0.54) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL24684965 0.86 QPCT (0.52) NPC1RAB9ASMN1; SMN2POLBMEN1
SCHEMBL1459333 0.83 NPC1 (0.56) NPC1RAB9ASMN1; SMN2POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112707868-B Benzimidazole-substituted halogenated phenyl n-butylamidine-based compound and preparation method thereof 山东福长药业有限公司 2023-09-15 CN disclosed
CN-114874212-B Preparation method of pentacyclic compound containing benzimidazole 嘉兴学院 2023-04-21 CN disclosed
US-20220054715-A1 Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto UNIV EMORY (US) 2022-02-24 US disclosed
US-20210371992-A1 ELECTROCHEMICAL ORGANIC REACTION SETUP AND METHODS PIRAMAL PHARMA LIMITED (IN) 2021-12-02 US disclosed
US-11179501-B2 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto EMORY UNIVERSITY (US) 2021-11-23 US disclosed
CN-111170947-A Preparation method of telmisartan impurity J 江苏中邦制药有限公司 2020-05-19 CN disclosed
US-20190224378-A1 Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto UNIV EMORY (US) 2019-07-25 US disclosed
US-10286113-B2 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto EMORY UNIVERSITY (US) 2019-05-14 US disclosed
US-20190023694-A1 BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA TANDON, VIBHA (IN) 2019-01-24 US disclosed
WO-2017125944-A1 BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA JAWAHARLAL NEHRU UNIVERSITY (JNU) (IN) 2017-07-27 WO disclosed
US-20160361470-A1 Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto UNIV EMORY (US) 2016-12-15 US disclosed
US-9056887-B2 Minor groove binder phosphoramidites and methods of use ELITECH HOLDING B.V. (NL) 2015-06-16 US disclosed
US-20140248372-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2014-09-04 US disclosed
WO-2013043529-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2013-03-28 WO disclosed
US-20130030166-A1 MINOR GROOVE BINDER PHOSPHORAMIDITES AND METHODS OF USE ELITECH HOLDING B.V. 2013-01-31 US disclosed
US-20090124814-A1 Process for preparing telmisartan PERLMAN NURIT 2009-05-14 US disclosed
US-7501448-B2 Process for preparing telmisartan TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2009-03-10 US disclosed
EP-1699765-A1 PROCESS FOR PREPARING TELMISARTAN Teva Pharmaceutical Industries Ltd (IL) 2006-09-13 EP disclosed
US-20060094883-A1 high yields, low cost process; easy solvent extraction; nontoxic, safe, environmentally friendly, low boiling point organic solvents; 1,7'-dimethyl-2'-propyl-1H,3'H-[2,5']bibenzoimidazolyl is reacted with 4'bromomethyl-biphenyl-2-carboxylic acid alkyl ester; industrial scale; hydrolysis TEVA PHARMACEUTICALS USA, INC. 2006-05-04 US disclosed
WO-2006044648-A1 PROCESS FOR PREPARING TELMISARTAN TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094883-A1 high yields, low cost process; easy solvent extraction; nontoxic, safe, environmentally friendly, low boiling point organic solvents; 1,7'-dimethyl-2'-propyl-1H,3'H-[2,5']bibenzoimidazolyl is reacted with 4'bromomethyl-biphenyl-2-carboxylic acid alkyl ester; industrial scale; hydrolysis AGT, ACE, REN NPC1 4197/4885RAB9A 3835/4885SMN1; SMN2 2165/4885
US-20090124814-A1 Process for preparing telmisartan AGT, ACE, REN NPC1 3908/4885RAB9A 3005/4885SMN1; SMN2 1859/4885
US-20160361470-A1 Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto BMP4, SOST, BMP2 NPC1 3847/4885RAB9A 479/4885SMN1; SMN2 3581/4885
US-20130030166-A1 MINOR GROOVE BINDER PHOSPHORAMIDITES AND METHODS OF USE PCNA, CD2BP2, BPGM NPC1 3751/4885RAB9A 4497/4885SMN1; SMN2 3714/4885
US-20190224378-A1 Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto BMP4, SOST, BMP2 NPC1 3847/4885RAB9A 479/4885SMN1; SMN2 3581/4885
US-20190023694-A1 BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA TOP2B, TOP2A, TOP1 NPC1 591/4885RAB9A 2107/4885SMN1; SMN2 4180/4885
US-20140248372-A1 BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO BMP4, SOST, BMP2 NPC1 3847/4885RAB9A 479/4885SMN1; SMN2 3581/4885
US-20220054715-A1 Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto BMP4, SOST, BMP2 NPC1 3847/4885RAB9A 479/4885SMN1; SMN2 3581/4885
US-11179501-B2 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto BMP4, SOST, BMP2 NPC1 3847/4885RAB9A 479/4885SMN1; SMN2 3581/4885
US-10286113-B2 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto BMP4, SOST, BMP2 NPC1 3847/4885RAB9A 479/4885SMN1; SMN2 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.